ArticleNPJ precision oncology2025

IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer.

Nicole M Kettner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.